Literature DB >> 17681085

Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia.

Shirly Amar1, Galit Shaltiel, Liad Mann, Alon Shamir, Brian Dean, Elizabeth Scarr, Yuly Bersudsky, R H Belmaker, Galila Agam.   

Abstract

Par-4 has been suggested to mediate dopamine neurotransmission. Dopamine D2 receptor (DRD2) activation induces a signalling complex of AKT1, PP2A and beta-arrestin2 which dephosphorylates/inactivates AKT1 thereby activating GSK-3beta, transducing dopamine-dependent behaviour. DRD2 activation also results in down-regulation of PKA activity. Among other substrates PKA phosphorylates GSK-3beta. Prolonged DRD2 activation leads to its 'desensitization' which involves GRKs and beta-arrestins. beta-arrestin1 binds to phosphorylated receptors preventing further G-protein stimulation. This study examined whether Par-4, beta-arrestin1, AKT1 and GSK-3beta are involved in the pathophysiology of schizophrenia. Lymphocytes obtained from schizophrenia and bipolar patients and healthy controls recruited from the Beer-Sheva Mental Health Center were transformed by Epstein-Barr virus (EBV) into lymphocyte-derived cell lines (LDCL). Post-mortem brain samples were obtained from the Rebecca L. Cooper Brain Bank, Parkville, Australia. The study was approved by the IRB committees of Beer-Sheva, Israel and Parkville, Australia. Levels of the specific proteins were assayed by Western blotting. beta-arrestin1 protein levels were significantly ~2-fold increased in LDCL from schizophrenia patients while Par-4 protein levels were unaltered. A 63% significant decrease was found in frontal cortex phospho-Ser9-GSK-3beta protein levels in schizophrenia but not in those of AKT1, Par-4 or beta-arrestin1. Elevated beta-arrestin1 protein levels in LDCL and decreased phospho-Ser9-GSK-3beta protein levels in post-mortem frontal cortex of schizophrenia patients vs. control groups support the possible involvement of these proteins in the pathophysiology of schizophrenia. However, since we did not find differences in beta-arrestin1, AKT1 and Par-4 protein levels in post-mortem frontal cortex of schizophrenia patients and although GSK-3beta participates in other signalling cascades we can not rule out the possibility that the differences found reflect deviation in DRD2 signalling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681085     DOI: 10.1017/S1461145707007948

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  15 in total

Review 1.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

Review 2.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

3.  Differential response of central dopaminergic system in acute and chronic unpredictable stress models in rats.

Authors:  Naila Rasheed; Ausaf Ahmad; Chandra Prakash Pandey; Rajnish Kumar Chaturvedi; Mohtashim Lohani; Gautam Palit
Journal:  Neurochem Res       Date:  2009-07-01       Impact factor: 3.996

4.  Altered serine/threonine kinase activity in schizophrenia.

Authors:  Jennifer L McGuire; John H Hammond; Stefani D Yates; Dongquan Chen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Brain Res       Date:  2014-04-26       Impact factor: 3.252

5.  Sex differences in the activity of signalling pathways and expression of G-protein-coupled receptor kinases in the neonatal ventral hippocampal lesion model of schizophrenia.

Authors:  Evgeny Bychkov; M Rafiuddin Ahmed; Eugenia V Gurevich
Journal:  Int J Neuropsychopharmacol       Date:  2010-02-17       Impact factor: 5.176

Review 6.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

7.  Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression.

Authors:  Leisa A Glantz; John H Gilmore; David H Overstreet; Kayvon Salimi; Jeffrey A Lieberman; L Fredrik Jarskog
Journal:  Schizophr Res       Date:  2010-01-13       Impact factor: 4.939

Review 8.  Molecular mechanisms of psychostimulant-induced structural plasticity.

Authors:  D M Dietz; K C Dietz; E J Nestler; S J Russo
Journal:  Pharmacopsychiatry       Date:  2009-05-11       Impact factor: 5.788

Review 9.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

Review 10.  Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sharonda S Harris; Nikhil M Urs
Journal:  CNS Drugs       Date:  2021-03-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.